Publications from FOR 2969

The amyloid proteome: a systematic review and proposal of a protein classification system.
Gottwald J, Röcken Ch.
Critical Reviews in Biochemistry and Molecular Biology 56, No 4, doi: 10.1080/10409238.2021.1937926 (2021) 

Cryo-EM reveals structural breaks in a patient-derived amyloid fibril from systemic AL amyloidosis.
Radamaker L, Baur J, Huhn S, Haupt CH, Hegenbart U, Schönland S, Bansal A, Schmidt M & Fändrich M.
Nature Communications 12, 875 (2021)

AA amyloid fibrils from diseased tissue are structurally different from in vitro formed SAA fibrils.
Bansal A, Schmidt M, Rennegarbe M, Haupt CH, Liberta F, Stecher S, Puscalau-Girtu I, Biedermann A & Fändrich M.
Nature Communications 12, 1013 (2021)

Seeded fibrils of the germline variant of human λ-III immunoglobulin light chain FOR005 have a similar core as patient fibrils with reduced stability.
Pradhan T, Annamalai K, Sarkar R, Huhn S, Hegenbart U, Schönland S, Fändrich M, Reif B.
Biological Chemistry 295 (52), 18474-18484 (2020)

Domain interactions determine the amyloidogenicity of antibody light chain mutants.
Weber B, Hora M, Kazman P, Pradhan T, Rührnößl F, Reif B, Buchner J.
Journal of Molecular Biology 432 (23), 6187-6199 (2020)

Solid state NMR assignments of a human λ-III immunoglobulin light chain amyloid fibril.
Pradhan T, Annamalai K, Sarkar R, Hegenbart U, Schönland S, Fändrich M, Reif B.
Biomolecular NMR Assignments, doi: 10.1007/s12104-020-09975-2 (2020)

Half a century of amyloids: past, present and future.
Ke PC, Zhou R, Serpell LC, Riek R, Knowles TPJ, Lashuel HA, Gazit E, Hamley IW, Davis TP, Fändrich M,
Otzen DE, Chapman MR, Dobson CM, Eisenberg DS, Mezzenga R.
Chemical Society Reviews 49, 5473-5509 (2020)

Fatal amyloid formation in a patient's antibody light chain is caused by a single point mutation.
Kazman P,  Vielberg MT, Pulido Cendales MD, Hunziger L, Weber B, Hegenbart U, Zacharias M,
Köhler, R, Schönland S, Groll M, Buchner J.
Elife 9, e52300 (2020)

Unraveling the complexity of amyloid polymorphism using gold nanoparticles an cryo-EM.
Cendrowska U, Silva PJ, Ait-Bouziad N, Müller M, Zekiye PG, Vieweg S, Chiki A, Radamaker L, Kumar ST, Fändrich M,
Tavanti F, Menziani MC, Alexander-Katz A, Stellacci F, Lashuel HA.
Proceedings of the National Academy of Science USA 117, 6866-6874 (2020)
 


 

Older publications:

Cryo-EM structure of a light chain-derived amyloid fibril from a patient with systemic AL amyloidosis.
Radamaker L, Lin Y-H, Annamalai K, Huhn S, Hegenbart U, Schönland SO, Fritz G, Schmidt M, Fändrich M.
Nature Communications 10, 1103 (2019)

Physical basis of amyloid fibril polymorphism.
Close W, Neumann M, Schmidt A, Hora M, Annamalai K, Schmidt M, Reif B, Schmidt V, Grigorieff N, Fändrich M.
Nature Communications 9, 699 (2018)

Lenalidomide/Melphalan/Dexamethasone in newly diagnosed patients with AL Amyloidosis: results of a prospective phase 2 study with long-term follow-up.
Hegenbart U, Bochtler T, Benner A, Becker N, Kimmich C, Kristen AV, Beimler J, Hund E, Zorn M, Freiberger A, Gawlik M, Goldschmidt H, Hose D, Jauch A, Ho AD, Schönland SO.
Haematologica 102, 1424-1431 (2017)

Common fibril structures imply systemically conserved protein misfolding pathways in vivo.
Annamalai K, Liberta F, Vielberg M-T, Close W, Lilie H, Gührs K-H, Schierhorn A, Koehler R, Schmidt A, Haupt C, Hegenbart U, Schönland SO, Schmidt M, Groll M, Fändrich M.
Angew. Chem Int Ed 56, 7510-7514 (2017)

Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myeloma.
da Silva Filho MI, Försti A, Weinhold N, Meziane I, Campo C, Huhn S, Nickel J, Hoffmann P, Nothen MM, Jockel KH, Landi S, Mitchell JS, Johnson D, Morgan GJ, Houlston R, Goldschmidt H, Jauch A, Milani P, Merlini G, Rowcieno D, Hawkins P, Hegenbart U, Palladini G, Wechalekar A, Schönland SO, Hemminki K.
Leukemia 31, 1735-1742 (2017)

Epigallocatechin-3-gallate preferentially induces aggregation of amyloidogenic immunoglobulin light chains.
Hora M, Carballo-Pacheco M, Weber B, Morris VK, Wittkopf A, Buchner J, Strodel B, Reif B.
Sci Rep 7, 41515 (2017)

A Stable Mutant Predisposes Antibody Domains to Amyloid Formation through Specific Non-Native Interactions.
Nokwe CN, Hora M, Zacharias M, Yagi H, Peschek J, Reif B, Goto Y, Buchner J.
Mol Biol 428, 1315-1332 (2016)

Cardiac amloid load: a prognostic and predictive biomarker at diagnosis prior to chemotherapy in AL amyloidosis.
Kristen AV, Brokbals E, Siepen F, Bauer R, Hein S, Aurich M, Riffel J, Behrens HM, Krüger S, Schirmacher P, Katus HA, Röcken C.
J Am Coll Cardiol 68, 13-24 (2016)

Polymorphism of Amyloid Fibrils In Vivo.
Annamalai K, Gührs KH, Koehler R, Schmidt M, Michel H, Loos C, Gaffney PM, Sigurdson CJ, Hegenbart U, Schönland SO, Fändrich M.
Angew Chem Int Ed 55, 4822-5 (2016)

Renal AA-amyloidosis in intravenous drug users - a role for HIV-infection?
Jung O, Haack HS, Buettner M, Betz C, Stephan C, Gruetzmacher P, Amann K, Bickel M.
BMC Nephrol 13, 151 (2012).

Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients.
Schönland SO, Hegenbart U, Bochtler T, Mangatter A, Hansberg O, Ho AD, Lohse P, Röcken C.
Blood 119, 488-93 (2012)